From May 21 to 23, 2025, the global laminopathy community will convene in the heart of Paris for the 5th International Meeting on Laminopathies, hosted at the historic Sorbonne Université – Campus des Cordeliers. This pivotal gathering marks a significant milestone for clinicians, scientists, and patient advocates dedicated to understanding and treating nuclear envelope disorders such as LMNA-related cardiomyopathies, Emery-Dreifuss muscular dystrophy, lipodystrophies, and progeroid syndromes.
Held every 2–3 years, this international meeting has become the central forum for advancing knowledge on laminopathies—rare genetic conditions caused by mutations in genes encoding nuclear envelope proteins. The 2025 edition brings together a diverse, interdisciplinary community of researchers, cardiologists, neurologists, geneticists, and patient groups committed to collaborative discovery and therapeutic innovation.
A Crossroads of Scientific Progress and Clinical Application
What sets the Laminopathies Meeting apart is its holistic approach. The program spans from basic nuclear envelope biology to clinical phenotypes and experimental treatments. Topics include:
-
Mechanisms of disease: Exploring how mutations in LMNA and related genes disrupt nuclear structure and function across tissues.
-
Cardiac and muscular manifestations: Highlighting progress in early diagnosis, risk stratification, and treatment strategies.
-
Laminopathic lipodystrophies and metabolic disorders: Addressing their underdiagnosis and emerging therapeutic options.
-
Therapeutic frontiers: From gene editing and RNA therapies to small molecules in preclinical pipelines.
-
Patient-centered dialogue: Integrating patient organizations into scientific discourse, reflecting the movement toward participatory medicine in rare diseases.
Leading Voices in the Field
The conference features over a dozen international experts who are shaping our understanding of laminopathies, including:
-
Dr. Philippe Collas (Norway) on genome organization and epigenetics in nuclear envelope disorders.
-
Dr. Vicente Andrés (Spain) and Dr. Susana Gonzalo (USA) on premature aging and cardiovascular pathology.
-
Dr. Giovanna Lattanzi (Italy) on chromatin dynamics and LMNA gene regulation.
-
Dr. Jean-Sébastien Hulot (France) on translational cardiology and therapeutic innovation.
-
Dr. Georgia Sarquella-Brugada (Spain) bringing a pediatric cardiology lens to LMNA syndromes.
This year’s meeting reflects an increasing emphasis on translational research and the path from bench to bedside, with presentations expected to highlight early-stage therapeutic programs and natural history insights crucial for trial design.
A Meeting With a Mission
For the global LMNA and laminopathy community, this meeting is more than a scientific exchange—it’s a statement of urgency and shared purpose. With no approved therapies for most laminopathies, the stakes are high. The collaborative atmosphere of the conference fosters partnerships that often extend beyond the event, supporting the rare disease ecosystem with momentum that continues year-round.
The 5th International Meeting also includes dedicated time for patient engagement, with a Patient Dinner and participation by advocacy organizations such as LMNAcardiac.org, Progeria Research Foundation, and various European networks. These bridges between patients and scientists help ensure that research priorities align with real-world needs.
Looking Ahead
As the laminopathy field gains visibility and research accelerates, the 5th International Meeting on Laminopathies stands as a key inflection point. It is a platform not only for scientific excellence but also for building the global alliances necessary to drive treatment development forward.
For updates and information, visit laminopathies.net or follow lmnacardiac.org for related news.
